Treatment of acute duodenal ulcers with famotidine and its comparison with other H2 blockers.

Famotidine, a new H2 antagonist in a dose of 40 mg qhs was tried in a clinical trial for the treatment of duodenal ulcer in 25 patients and compared with other H2 antagonists. Cimetidine 800 mg qhs and Ranitidine 300 mg qhs were used in a similar number of randomised patients. Patients were evaluated clinically, biochemically and endoscopically. At the end of eight weeks, the healing rate with Famotidine was 96%. Cimetidine was 92% and Ranitidine 96%. No significant side effects were noted with any of these drugs. In conclusion, Famotidine (40 mg qhs) is an effective and generally well-tolerated drug in the treatment of acute duodenal ulcer.

RCT Entities:   Population Interventions Outcomes